Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Kyprolis

Carfilzomib

RLDNDA 202714 3 strengths Onyx Pharms Amgen
Approved
Jul 20, 2012
Strengths
3
Listed patents
8

What does the FDA Orange Book show for Kyprolis?

Kyprolis contains Carfilzomib and is the new drug FDA Orange Book record for NDA 202714. The application has 3 presentations with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 202714

New drug application identity from the Orange Book snapshot.

Application holder
Onyx Pharmaceuticals Inc A Wholly Owned Sub Of Amgen Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
3

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
AP

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
8

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
2

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
00160MG/VIALPOWDERINTRAVENOUSPrescriptionAP
RLDRS
00230MG/VIALPOWDERINTRAVENOUSPrescriptionNone posted
RLDRS
00310MG/VIALPOWDERINTRAVENOUSPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Onyx Pharmaceuticals Inc A Wholly Owned Sub Of Amgen Inc

The Orange Book identifies this organization as the applicant responsible for NDA 202714.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

3 presentations listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

TE code AP across rated presentations

An AP code is an A-rating: FDA considers the product therapeutically equivalent to pharmaceutical equivalents in the same Orange Book heading and equivalence group. 2 presentations in the application have no posted TE code.

Patent & exclusivity record

7 listed patent expirations and 2 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Aug 27, 2033. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

4 other ANDAs and 0 other NDAs found

1 of the related ANDA application is not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 202714 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-202714

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

3 approved presentations · NDA 202714
TE APRLDRS
Strength
60MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    14 yr 3 mo ago

  2. Patent 7417042 expires

    Listed drug substance patent expiration.

    6 d ago

  3. Today

  4. Patent 7417042*PED expires

    Listed listed patent expiration.

    in 6 mo

  5. Patent 7737112 expires

    Listed drug product patent expiration.

    in 1 yr 5 mo

  6. Exclusivity ends · M-14

    New use / labeling-change exclusivity (3 years)

    in 1 yr 10 mo

  7. Patent 7737112*PED expires

    Listed listed patent expiration.

    in 1 yr 11 mo

  8. Exclusivity ends · PED

    Pediatric exclusivity (adds 6 months)

    in 2 yr 4 mo

  9. Patent RE47954 expires

    Listed method-of-use patent (U-3449) expiration.

    in 3 yr 3 mo

  10. Patent RE47954*PED expires

    Listed listed patent expiration.

    in 3 yr 10 mo

  11. Patent 9493582 expires

    Listed drug product patent expiration.

    in 6 yr 8 mo

  12. Patent 9493582*PED expires

    Listed listed patent expiration.

    in 7 yr 2 mo

Patent & exclusivity timeline

Protection horizon
202620272028202920302031203220332034TodayPatent 7417042: 2026-07-20Patent 7417042Patent 7417042*PED: 2027-01-20Patent 7417042*PEDPatent 7737112: 2027-12-07Patent 7737112Exclusivity M-14: 2028-05-22Exclusivity M-14Patent 7737112*PED: 2028-06-07Patent 7737112*PEDExclusivity PED: 2028-11-22Exclusivity PEDPatent RE47954: 2029-10-21Patent RE47954Patent RE47954*PED: 2030-04-21Patent RE47954*PEDPatent 9493582: 2033-02-27Patent 9493582Patent 9493582*PED: 2033-08-27Patent 9493582*PED
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

CARFILZOMIB

Strength

60MG/VIAL

Dosage form

POWDER

Route

INTRAVENOUS

TE code

AP

Application

NDA 202714

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Marketing exclusivity

Hatch-Waxman
  • M-14New use / labeling-change exclusivity (3 years)

    in 1 yr 10 mo

  • PEDPediatric exclusivity (adds 6 months)

    in 2 yr 4 mo

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
74170426 d ago
SubstanceProduct
7417042*PEDin 6 mo
7737112in 1 yr 5 mo
Product
7737112*PEDin 1 yr 11 mo
RE47954in 3 yr 3 mo
U-3449
RE47954*PEDin 3 yr 10 mo
9493582in 6 yr 8 mo
Product
9493582*PEDin 7 yr 2 mo

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Carfilzomib family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Kyprolis: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 202714 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo